Details for New Drug Application (NDA): 020784
✉ Email this page to a colleague
NDA 020784 describes NASACORT HFA, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. Additional details are available on the NASACORT HFA profile page.
The generic ingredient in NASACORT HFA is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
The generic ingredient in NASACORT HFA is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Summary for 020784
| Tradename: | NASACORT HFA |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | triamcinolone acetonide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020784
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY, METERED;NASAL | Strength | 0.055MG/SPRAY | ||||
| Approval Date: | Apr 7, 2004 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
